Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741598 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT00741598 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 72 participants.
The verdict
NCT00741598, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder.
Interventions
- DRUG Galantamine-ER
- DRUG Galantamine placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741598
The ClinicalTrials.gov registry entry for NCT00741598 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Galantamine-ER is the first listed.
NCT00741598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741598 about?
NCT00741598 is a clinical study titled "Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder". This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder.
What is the current status of trial NCT00741598?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2008-09. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00741598?
The interventions under investigation include: Galantamine-ER (DRUG), Galantamine placebo (DRUG).
Who is sponsoring clinical trial NCT00741598?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.